Related Experiment Video
Updated: Jun 12, 2026
07:08
Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood
Published on: September 5, 2017
Aspects of anticoagulation in children
1Department of Paediatric Haematology, Sheffield Children's Hospital, Sheffield, UK. jeanette.payne@sch.nhs.uk
British Journal of Haematology
|June 10, 2010
Summary
Pediatric anticoagulation is growing, but optimal management, especially for asymptomatic events, needs more research. Current practices often rely on adult data, highlighting a need for specific pediatric studies on traditional and novel anticoagulants.
Area of Science:
- Pediatric Hematology
- Thrombosis and Hemostasis
- Pharmacology
Background:
- Increasing use of anticoagulation in children necessitates better understanding of treatment efficacy and safety.
- Thromboembolic events in pediatric patients carry significant morbidity and mortality risks.
- Optimal management strategies for asymptomatic thromboembolic events in children remain undefined.
Purpose of the Study:
- To review the challenges and current state of pediatric anticoagulation.
- To evaluate the limitations of traditional anticoagulants in children.
- To explore the potential of newer anticoagulant agents in pediatric populations.
Main Methods:
- Review of existing registry and observational studies in pediatric anticoagulation.
- Analysis of challenges in pediatric thrombosis diagnosis and anticoagulation management.
- Examination of adult clinical trial data and preliminary pediatric findings for alternative agents.
Main Results:
- Pediatric anticoagulation presents unique challenges due to age-related changes in hemostatic systems.
- Traditional anticoagulants like heparin and warfarin have unanswered questions regarding optimal use in children.
- Emerging agents like direct thrombin inhibitors and fondaparinux show promise but require dedicated pediatric trials.
Conclusions:
- Current pediatric anticoagulation practices are largely extrapolated from adult studies.
- There is a critical need for robust, prospective pediatric studies to guide safe and effective anticoagulation.
- Novel anticoagulant agents may offer advantages, but their pediatric safety and efficacy are not yet fully established.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:29Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...